Benjamin Weide

Few, but Efficient: The Role of Mast Cells in Breast Cancer and Other Solid Tumors

Platelet factor 4–induced T _H 1-T _reg polarization suppresses antitumor immunity

Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy

Elements of cancer immunity and the cancer–immune set point

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

High-Voltage Electrical Pulses in Oncology: Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, Electrofusion, and Electroimmunotherapy

Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016

The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth

A systematic review shows no performance benefit of machine learning over logistic regression for clinical prediction models

Immune checkpoint inhibitors: recent progress and potential biomarkers

Which melanoma patient carries a BRAF-mutation? A comparison of predictive models

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma

Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy

Osteopontin at the Crossroads of Inflammation and Tumor Progression

Survival According to BRAF-V600 Tumor Mutations – An Analysis of 437 Patients with Primary Melanoma

Immunologic Correlates in the Course of Treatment With Immunomodulating Antibodies

Melanoma staging: Facts and controversies

Incisional biopsy and melanoma prognosis: Facts and controversies

Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis

Targeting tumor-resident mast cells for effective anti-melanoma immune responses